Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Capstone Holding Corp. Director's Dealing 2008

Oct 15, 2008

35323_dirs_2008-10-15_dcb2fb81-9980-4b06-b07c-37770ce47ae8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORTHOLOGIC CORP (CAPS)
CIK: 0000887151
Period of Report: 2008-10-10

Reporting Person: BVF PARTNERS L P/IL (10% Owner, Indirect Beneficial Owner)
Reporting Person: BIOTECHNOLOGY VALUE FUND L P (Direct Beneficial Owner)
Reporting Person: BIOTECHNOLOGY VALUE FUND II LP (Direct Beneficial Owner)
Reporting Person: BVF INVESTMENTS LLC (Direct Beneficial Owner)
Reporting Person: BVF INC/IL (10% Owner, Indirect Beneficial Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2008-10-10 Common Stock P 56500 $.5758 Acquired 4006788 Indirect
2008-10-10 Common Stock P 39000 $.5758 Acquired 4045788 Indirect
2008-10-10 Common Stock P 142000 $.5758 Acquired 4187788 Indirect
2008-10-13 Common Stock P 1600 $.6301 Acquired 4189388 Indirect
2008-10-13 Common Stock P 1000 $.6301 Acquired 4190388 Indirect
2008-10-14 Common Stock P 221400 $.63 Acquired 4411788 Indirect
2008-10-14 Common Stock P 153000 $.63 Acquired 4564788 Indirect
2008-10-14 Common Stock P 557000 $.63 Acquired 5121788 Indirect
2008-10-14 Common Stock P 3100 $.7484 Acquired 5124888 Indirect
2008-10-14 Common Stock P 3000 $.7484 Acquired 5127888 Indirect
2008-10-14 Common Stock P 9000 $.7484 Acquired 5136888 Indirect

Footnotes

F1: The shares reported in this response are indirectly beneficially owned by BVF Partners L.P., a Delaware limited partnership ("Partners"), the designated filer of this joint filing on Form 4, and by its general partner, BVF Inc., a Delaware corporation ("BVF Inc."), which is also an investment advisor to Partners. Partners is the general partner of Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF, L.P.") and Biotechnology Value Fund II, L.P., a Delaware limited partnership ("BVF2, L.P."), both investment limited partnerships. Partners also is the manager of BVF Investments, L.L.C., a Delaware limited liability company ("Investments"). Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest the funds of Ziff Asset Management, L.P., the majority member of Investments, in the shares of Common Stock reported in Table I as being beneficially owned by Investments.

F2: Mark N. Lampert is the sole shareholder and sole director of BVF Inc., and is an officer of BVF Inc. This joint filing on Form 4 shall not be deemed an admission that Mark N. Lampert is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any equity securities covered by this joint filing.

F3: Shares directly beneficially owned by BVF, L.P.

F4: Shares directly beneficially owned by BVF2, L.P.

F5: Shares directly beneficially owned by Investments.

F6: Total amount of shares indirectly beneficially owned by Partners and BVF Inc.